which will also see Novo Nordisk take direct ownership of three Catalent sites where injection pens are filled in Italy, ...

Novo Nordisk’s majority shareholder Novo Holdings is buying Catalent for $16.5 billion, and then selling the three fill-and-finish facilities in the US, Belgium, and Italy to Novo Nordisk for ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

Catalent will continue to operate independently and separately from Novo Holdings and Novo Nordisk. The three sites in Anagni, Italy, Brussels in Belgium, and Bloomington, Indiana, in the US will ...

After the deal closes, Novo Holdings will sell three of Catalent's fill-finish sites - in Italy, Belgium and the United States - onto Novo Nordisk for $11 billion. The sites will then by fully ...